(Q81604925)
Statements
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer (English)
T G Ehlen
P J Hoskins
D Miller
T L Whiteside
C F Nicodemus
B C Schultes